Rienso

RSS

Withdrawn

This medicine's authorisation has been withdrawn

ferumoxytol
MedicineHumanWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 13 April 2015, the European Commission withdrew the marketing authorisation for Rienso (ferumoxytol) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Rienso was granted marketing authorisation in the EU on 15 June 2012 for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Rienso is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (626.83 KB - PDF)

Zobrazit

español (ES) (541.35 KB - PDF)

Zobrazit

čeština (CS) (606.5 KB - PDF)

Zobrazit

dansk (DA) (540.89 KB - PDF)

Zobrazit

Deutsch (DE) (564.41 KB - PDF)

Zobrazit

eesti (ET) (544.54 KB - PDF)

Zobrazit

ελληνικά (EL) (629.77 KB - PDF)

Zobrazit

français (FR) (564.64 KB - PDF)

Zobrazit

hrvatski (HR) (563.78 KB - PDF)

Zobrazit

italiano (IT) (545.59 KB - PDF)

Zobrazit

latviešu (LV) (606.35 KB - PDF)

Zobrazit

lietuvių (LT) (565.85 KB - PDF)

Zobrazit

magyar (HU) (600.58 KB - PDF)

Zobrazit

Malti (MT) (609.06 KB - PDF)

Zobrazit

Nederlands (NL) (542.02 KB - PDF)

Zobrazit

polski (PL) (603.97 KB - PDF)

Zobrazit

português (PT) (547.26 KB - PDF)

Zobrazit

română (RO) (565.46 KB - PDF)

Zobrazit

slovenčina (SK) (606.88 KB - PDF)

Zobrazit

slovenščina (SL) (598.33 KB - PDF)

Zobrazit

suomi (FI) (561.26 KB - PDF)

Zobrazit

svenska (SV) (563.36 KB - PDF)

Zobrazit

Product information

български (BG) (1.69 MB - PDF)

Zobrazit

español (ES) (965.83 KB - PDF)

Zobrazit

čeština (CS) (1.42 MB - PDF)

Zobrazit

dansk (DA) (1.04 MB - PDF)

Zobrazit

Deutsch (DE) (1013.47 KB - PDF)

Zobrazit

eesti (ET) (990.64 KB - PDF)

Zobrazit

ελληνικά (EL) (1.74 MB - PDF)

Zobrazit

français (FR) (1022.83 KB - PDF)

Zobrazit

hrvatski (HR) (1007.46 KB - PDF)

Zobrazit

italiano (IT) (1013.36 KB - PDF)

Zobrazit

latviešu (LV) (1.47 MB - PDF)

Zobrazit

lietuvių (LT) (1.02 MB - PDF)

Zobrazit

magyar (HU) (1.49 MB - PDF)

Zobrazit

Malti (MT) (1.47 MB - PDF)

Zobrazit

Nederlands (NL) (974.35 KB - PDF)

Zobrazit

polski (PL) (1.45 MB - PDF)

Zobrazit

português (PT) (988.58 KB - PDF)

Zobrazit

română (RO) (1.02 MB - PDF)

Zobrazit

slovenčina (SK) (1.48 MB - PDF)

Zobrazit

slovenščina (SL) (1.44 MB - PDF)

Zobrazit

suomi (FI) (1.01 MB - PDF)

Zobrazit

svenska (SV) (976.7 KB - PDF)

Zobrazit

Íslenska (IS) (1004.63 KB - PDF)

Zobrazit

norsk (NO) (989.08 KB - PDF)

Zobrazit
Latest procedure affecting product information:PSUV/0015
13/04/2015
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (507.08 KB - PDF)

Zobrazit

español (ES) (472.73 KB - PDF)

Zobrazit

čeština (CS) (499.29 KB - PDF)

Zobrazit

dansk (DA) (472.04 KB - PDF)

Zobrazit

Deutsch (DE) (469.24 KB - PDF)

Zobrazit

eesti (ET) (474.46 KB - PDF)

Zobrazit

ελληνικά (EL) (506.91 KB - PDF)

Zobrazit

français (FR) (472.9 KB - PDF)

Zobrazit

hrvatski (HR) (487.11 KB - PDF)

Zobrazit

italiano (IT) (471.48 KB - PDF)

Zobrazit

latviešu (LV) (506.28 KB - PDF)

Zobrazit

lietuvių (LT) (485.47 KB - PDF)

Zobrazit

magyar (HU) (488.44 KB - PDF)

Zobrazit

Malti (MT) (497.29 KB - PDF)

Zobrazit

Nederlands (NL) (469.38 KB - PDF)

Zobrazit

polski (PL) (497.46 KB - PDF)

Zobrazit

português (PT) (472.94 KB - PDF)

Zobrazit

română (RO) (492.54 KB - PDF)

Zobrazit

slovenčina (SK) (503.83 KB - PDF)

Zobrazit

slovenščina (SL) (487.68 KB - PDF)

Zobrazit

suomi (FI) (470.68 KB - PDF)

Zobrazit

svenska (SV) (471.89 KB - PDF)

Zobrazit

Íslenska (IS) (475.22 KB - PDF)

Zobrazit

norsk (NO) (470.92 KB - PDF)

Zobrazit

Product details

Name of medicine
Rienso
Active substance
Ferumoxytol
International non-proprietary name (INN) or common name
ferumoxytol
Therapeutic area (MeSH)
  • Anemia
  • Kidney Failure, Chronic
Anatomical therapeutic chemical (ATC) code
B03

Pharmacotherapeutic group

Other antianemic preparations

Therapeutic indication

Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).

The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).

Authorisation details

EMA product number
EMEA/H/C/002215
Marketing authorisation holder
Takeda Pharma A/S

P.O. Box 260
Dybendal Alle 10
2630 Taastrup
Denmark

Marketing authorisation issued
15/06/2012
Withdrawal of marketing authorisation
13/04/2015
Revision
7

Assessment history

This page was last updated on

Share this page